Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 5993 versus Relvar + Spiriva in severe COPD
NL-OMON41888Phase 3Active, not recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium, fluticasone propionate + vilanterol and tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change from baseline in SGRQ total score at Week 26. Started Dec 2015; status: active, not recruiting.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrroniumfluticasone propionate + vilanteroltiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON41888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41888.